Page last updated: 2024-08-26

levobupivacaine and ER-Negative PR-Negative HER2-Negative Breast Cancer

levobupivacaine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Benedetti, E; Castelli, V; Cimini, A; d'Angelo, M; Giordano, A; Ippoliti, R; Marinangeli, F; Paladini, A; Piroli, A; Varrassi, G; Zis, P1

Other Studies

1 other study(ies) available for levobupivacaine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Local anesthetics counteract cell proliferation and migration of human triple-negative breast cancer and melanoma cells.
    Journal of cellular physiology, 2020, Volume: 235, Issue:4

    Topics: Anesthetics, Local; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Levobupivacaine; Melanoma; Ropivacaine; Signal Transduction; Triple Negative Breast Neoplasms

2020